“Salami-slicing” the cost of medicines, which represent almost one-fifth of health system budgets and are subject to rigorous value assessments, won’t make healthcare systems more sustainable in the future, Nathalie Moll told EURACTIV.com in an interview.
The African Unions EU representative, Ajay Bramdeo, told EURACTIV Germany that plans for a Marshall Plan for Africa are fundamentally good but warned that the continent needs to be the focus and that healthcare must be the priority.
Alzheimer’s disease and other forms of dementia remain underdiagnosed in most European countries, Jean Georges told EURACTIV.
A new breed of drugs, called “value added medicines”, could help patients improve their everyday life while in treatment, without increasing healthcare budgets, Christoph Stoller said in an interview with EURACTIV.com
EXCLUSIVE: The great tragedy for the pharmaceutical industry is that it keeps denying that it lobbies against transparency in clinical trials, says Ben Goldacre.
The lack of gender balance in clinical tests affects almost all medical sectors, but is particularly relevant in cardiovascular diseases where only 33% of trials participants are women. On International Women's Day, Marco Stramba-Badiale is calling for an update of the EU's Clinical Trials Directive to address this imbalance.
The European Commission's proposed regulation on clinical trials will help the European pharma industry to stop research centres from fleeing to Asia and America, says Philippe Juvin, a French centre-right MEP.
